MMRGlobal, Inc. announced that it has received another significant milestone payment pursuant to an existing Non-Exclusive License Agreement (the "Agreement") pertaining to the Company's biotech assets. The non-exclusive Agreement licenses the use of the Company's clinical and scientific data relating to targeted immunotherapies for cancer and other disease treatments to stimulate a patient's immune response and certain other confidential information. MMRGlobal's licensed assets are part of the Company's worldwide intellectual property rights to numerous biotech assets including international patents, vaccine and patient samples and anti-CD20 monoclonal antibodies.